US Patent

US9555023 — Pharmaceutical salts and polymorphs of a factor Xa inhibitor

Method of Use · Assigned to Millennium Pharmaceuticals Inc · Expires 2026-11-07 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical salts and polymorphs of a factor Xa inhibitor, specifically compounds with Formula I.

USPTO Abstract

The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.

Drugs covered by this patent

Bevyxxa (BETRIXABAN) · Portola Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1502`	—	Bevyxxa
`U-1502`	—	Bevyxxa

Patent Metadata

Patent number: US9555023
Jurisdiction: US
Classification: Method of Use
Expires: 2026-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Millennium Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.